1. Erratum to “Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma” [Gynecol Oncol. 120 (2011) 11–17] 
Heini Lassus, Synnöve Staff, Arto Leminen, Jorma Isola, Ralf Butzow 
Gynecologic Oncology 
Volume 125, Issue 1, Pages (April 2012)
DOI: /j.ygyno
Copyright © 2011 Elsevier Inc. Terms and Conditions

2. Fig. 1
Examples of immunohistochemical staining and CISH of Aurora-A: (A) normal serous epithelium of fallopian tube with Aurora-A immunostaining, (B) normal ovarian surface epithelium with Aurora-A immunostaining, (C) serous ovarian carcinoma showing negative immunostaining of Aurora-A, (D) serous ovarian carcinoma showing positive cytoplasmic immunostaining of Aurora-A, (E) serous ovarian carcinoma showing positive nuclear immunostaining of Aurora-A, (F) serous ovarian carcinoma showing Aurora-A gene amplification by CISH, (G) normal serous epithelium of fallopian tube with immunostaining of phosphorylated Aurora-A, (H) serous ovarian carcinoma showing negative immunostaining of phosphorylated Aurora-A and (I) serous ovarian carcinoma showing positive immunostaining of phosphorylated Aurora-A.
Gynecologic Oncology  , DOI: ( /j.ygyno )
Copyright © 2011 Elsevier Inc. Terms and Conditions